ClinicalTrials.gg
Active, not recruitingNCT04765059COMPELUpdated Jul 7, 2026Results posted

A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)

A Phase 3 interventional study of Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin and Placebo for osimertinib (AZD9291) pemetrexed cisplatin or carboplatin in Non-small Cell Lung Cancer, sponsored by AstraZeneca. Active, not recruiting at 40 sites in 6 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-07-07.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung — 20 open to participants now, 43 under way, 8 of them phase 3. osimertinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
31st of 90
98 · median 51
Started
2021
with 9 others
Phase 3
12 of 90
1 open now
Primary completion
2024-10
later than 8 of 42 live
Registered
58th of 90
by date
Lead sponsor
29 of 90
AstraZeneca

Among the 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung, this one is the 31st largest by enrollment, is one of 10 that started in 2021, is one of 12 in phase 3, reaches primary completion later than 8 of the 42 other live ones, and was the 58th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

20 of the 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung are open now, in 7 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About osimertinib

osimertinib: first FDA approval 2015 (TAGRISSO), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The study will evaluate the efficacy and safety of treatment with chemotherapy in combination with osimertinib compared to chemotherapy in combination with placebo in patients whose disease has progressed extracranially following first-line osimertinib treatment.

Read the detailed description

This is a Phase III, randomized, double-blind, placebo-controlled study of platinum plus pemetrexed chemotherapy plus osimertinib versus platinum plus pemetrexed chemotherapy plus placebo in patients with epidermal growth factor receptor mutation-positive (EGFRm), locally advanced or metastatic NSCLC with or wihout stable brain metastases who responded to first-line osimertinib therapy (complete response [CR] or partial response [PR]) or stable disease (SD) for ≥ 6 months during first-line osimertinib treatment, and subsequently experienced radiological, extracranial disease progression. Approximately 204 patients were to be randomized in a 1:1 ratio to treatment with platinum plus pemetrexed chemotherapy plus osimertinib (Treatment Arm A) or platinum plus pemetrexed chemotherapy plus placebo (Treatment Arm B). However, the number of patients has been reduced to approximately 80 patients due to treatment landscape changes which outpaced study recruitment. Patients will be stratified based on the presence of brain metastases (stable brain metastases based on central nervous system (CNS) Response Evaluation Criteria in Solid Tumors, Version 1.1 [RECIST 1.1] assessments versus no brain metastases).

The 2 randomized treatment regimens are as follows:

  • Treatment Arm A: Osimertinib 80 mg once daily (QD) with pemetrexed (500 mg/m\^2) (with pre-treatment) plus either cisplatin (75 mg/m\^2) or carboplatin (area under the concentration-time curve [AUC] 5), both administered on Day 1 of 21-day cycles for 4 cycles, followed by osimertinib 80 mg QD plus pemetrexed maintenance (500 mg/m\^2) on Day 1 of 21-day cycles
  • Treatment Arm B: Placebo QD with pemetrexed (500 mg/m\^2) (with pre-treatment) plus either cisplatin (75 mg/m\^2) or carboplatin (AUC5), both administered on Day 1 of 21-day cycles for 4 cycles, followed by placebo QD plus pemetrexed maintenance (500 mg/m\^2) on Day 1 of 21-day cycles.
03

Conditions studied

  • Non-small Cell Lung Cancer

Keywords

  • Osimertinib
  • Platinum
  • Pemetrexed
  • Epidermal growth factor receptor mutation positive (EGFRm)
  • Extracranial progression
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Capable of giving signed , which includes compliance with the requirements and restrictions listed in the informed consent form and in this protocol.
  2. confirmed non-squamous NSCLC.
  3. Locally advanced (clinical stage IIIB or IIIC) or NSCLC (clinical stage IVA or IVB) or recurrent NSCLC, not amenable to curative surgery or radiotherapy.
  4. Evidence of radiological extracranial disease progression following (Investigator-assessed) response or SD for ≥ 6 months during osimertinib treatment, but who have not received further, subsequent treatment.
  5. Tumor known to harbor 1 of the 2 or both common epidermal growth factor receptor (EGFR) mutations known to be associated with EGFR tyrosine kinase inhibitor (TKI) sensitivity (Ex19del or L858R), either alone or in combination with other EGFR mutations, which may include T790M.
  6. World Health Organization performance status of 0 to 1 at screening with no deterioration in the previous 2 weeks.
  7. >12 weeks at Day 1.
  8. At least 1 lesion, not previously irradiated, that can be accurately measured.
  9. Females must be using highly effective measures, and must have a negative pregnancy test prior to start of dosing if of , or must have evidence of non-childbearing potential by fulfilling criteria at screening.
  10. Male patients must be willing to use barrier contraception

Exclusion criteria

Exclusion Criteria:

  1. Clinical or radiological evidence of CNS progression on osimertinib.
  2. Past medical history of interstitial lung disease (ILD)/pneumonitis, drug-induced ILD/pneumonitis, radiation pneumonitis that required treatment, or any evidence of clinically active ILD/pneumonitis.
  3. Any evidence of severe or uncontrolled systemic diseases.
  4. Any of the following cardiac criteria:

    i) Mean resting >470 msec ii) Any abnormalities in rhythm, conduction, or morphology of resting iii) Any factors that increase the risk of QTc prolongation or risk of arrhythmic events

  5. Any concurrent and/or other active that has required treatment within 2 years of first dose of product (IP).
  6. Any unresolved toxicities from prior therapy.
  7. nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of osimertinib.
  8. More than 4 weeks elapsed since last dose of osimertinib by date of randomization.
  9. Unable to tolerate osimertinib 80 mg first-line therapy.
  10. Prior treatment with any systemic anti-cancer therapy.
  11. Major surgery within 4 weeks of the first dose of IP.
  12. Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of IP.
  13. Current use of medications or herbal supplements known to be strong inducers of cytochrome P450 (CYP) 3A4.
  14. Participation in another clinical study with an IP other than first-line osimertinib during the 4 weeks prior to Day 1.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
98 participants (actual)

Study arms

  • Experimental
    Treatment Arm A

    All randomized patients will receive osimertinib 80 mg QD with pemetrexed (500 mg/m\^2) (with pre-treatment) plus either cisplatin (75 mg/m\^2) or carboplatin (\[AUC\] 5), both administered on Day 1 of 21-day cycles for 4 cycles, followed by osimertinib 80 mg QD plus pemetrexed maintenance (500 mg/m\^2) on Day 1 of 21-day cycles

    Drug: Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin

  • Placebo comparator
    Treatment Arm B

    All randomized patients will receive placebo QD with pemetrexed (500 mg/m\^2) (with pre-treatment) plus either cisplatin (75 mg/m\^2) or carboplatin (AUC5), both administered on Day 1 of 21-day cycles for 4 cycles, followed by placebo QD plus pemetrexed maintenance (500 mg/m\^2) on Day 1 of 21-day cycles

    Drug: Placebo for osimertinib (AZD9291) pemetrexed cisplatin or carboplatin

Interventions

  • Randomized patients will receive oral dose of osimertinib with intravenous (IV) pemetrexed plus either IV cisplatin or IV carboplatin

  • DrugPlacebo for osimertinib (AZD9291) pemetrexed cisplatin or carboplatin

    Randomized patients will receive oral dose of placebo matching osimertinib with IV pemetrexed plus either IV cisplatin or IV carboplatin

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    Progression free survival is defined as time from randomization until progression (intracranial or extracranial, whichever occurs first) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (for extracranial progression) and Central nervous system (CNS) RECIST 1.1 (for intracranial progression) as assessed by the Investigator at local site or death due to any cause.

    Time frame: From date of first dose (Day 1) until date of progression at local site or death due to any cause or data cut-off date whichever occurred first (up to 3 years 1 month)

Secondary outcomes

  1. Intracranial Progression Free Survival in Participants With Brain Metastases at Baseline

    Intracranial PFS (IC-PFS) is defined as time from randomization until intracranial progression per CNS RECIST 1.1 as assessed by the Investigator at local site or death due to any cause. For participants with brain metastases at baseline, the IC-PFS rate at specified timepoints was estimated using the Kaplan-Meier method which indicated the percentage of these participants who remain alive and free from intracranial progression per CNS RECIST 1.1 as assessed by the Investigator. The data was calculated throughout the study as per the below timeframe but IC-PFS rate at 6 months has been presented as it was clinically relevant.

    Time frame: Assessed from date of first dose (Day 1) until date of intracranial progression at local site or death due to any cause or data cut off date whichever occurred first (up to 3 years 1 month), data for 6 months reported

  2. Intracranial Progression Free Survival in Participants Without Brain Metastases at Baseline

    Intracranial PFS (IC-PFS) is defined as time from randomization until intracranial progression per CNS RECIST 1.1 as assessed by the Investigator at local site or death due to any cause. For participants without brain metastases at baseline, the IC-PFS rate at specified timepoints was estimated using the Kaplan-Meier method which indicated the percentage of these participants who remain alive and free from intracranial progression per CNS RECIST 1.1 as assessed by the Investigator. The data was calculated throughout the study as per the below timeframe but IC-PFS rate at 6 months has been presented as it was clinically relevant.

    Time frame: Assessed from date of first dose (Day 1) until date of intracranial progression at local site or death due to any cause or data cut off date whichever occurred first (up to 3 years 1 month), data for 6 months reported

  3. Extracranial Progression Free-survival

    Extracranial PFS is defined as time from randomization until extracranial progression per RECIST 1.1 as assessed by the Investigator at local site or death due to any cause.

    Time frame: From date of first dose (Day 1) until date of extracranial progression at local site or death due to any cause or data cut-off date whichever occurred first (up to 3 years 1 month)

  4. Overall Survival (OS)

    Overall survival is defined as the length of time from randomization until the date of death due to any cause.

    Time frame: From date of first dose (Day 1) until post progression survival follow-up (up to 3 years 1 month)

07

Results

Posted Jan 13, 2026

Participant flow

Participants were enrolled in this study from 12 September 2021 (First participant in) and the analyses presented in this results form are based on a final data cut-off of 28 October 2024.

Participant flow — Overall Study
MilestoneTreatment Arm A: Osimertinib (AZD9291), Pemetrexed, Cisplatin or CarboplatinTreatment Arm B: Placebo for Osimertinib (AZD9291), Pemetrexed, Cisplatin or Carboplatin
Started4949
Completed00
Not completed4949
Withdrew: Failure to meet randomization criteria10
Withdrew: Withdrawal by subject14
Withdrew: Lost to follow-up11
Withdrew: Death2528
Withdrew: Participants ongoing study at data cutoff date of 28-oct-242116

Outcome measures

PrimaryProgression Free Survival (PFS)

Progression free survival is defined as time from randomization until progression (intracranial or extracranial, whichever occurs first) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (for extracranial progression) and Central nervous system (CNS) RECIST 1.1 (for intracranial progression) as assessed by the Investigator at local site or death due to any cause.

Time frame:
From date of first dose (Day 1) until date of progression at local site or death due to any cause or data cut-off date whichever occurred first (up to 3 years 1 month)
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsTreatment Arm A: Osimertinib (AZD9291), Pemetrexed, Cisplatin or CarboplatinTreatment Arm B: Placebo for Osimertinib (AZD9291), Pemetrexed, Cisplatin or Carboplatin
Progression Free Survival (PFS)8.4 (5.75 to 11.83)4.4 (3.52 to 5.55)
Statistical analysis
  • Treatment Arm A: Osimertinib (AZD9291), Pemetrexed, Cisplatin or Carboplatin vs Treatment Arm B: Placebo for Osimertinib (AZD9291), Pemetrexed, Cisplatin or Carboplatin · Log Rank · Hazard ratio (hr): 0.43 · 95% CI 0.27 to 0.70A hazard ratio \< 1 favours Osi+Cis/Carbo+Pem to be associated with a longer progression-free survival than placebo.
SecondaryIntracranial Progression Free Survival in Participants With Brain Metastases at Baseline

Intracranial PFS (IC-PFS) is defined as time from randomization until intracranial progression per CNS RECIST 1.1 as assessed by the Investigator at local site or death due to any cause. For participants with brain metastases at baseline, the IC-PFS rate at specified timepoints was estimated using the Kaplan-Meier method which indicated the percentage of these participants who remain alive and free from intracranial progression per CNS RECIST 1.1 as assessed by the Investigator. The data was calculated throughout the study as per the below timeframe but IC-PFS rate at 6 months has been presented as it was clinically relevant.

Time frame:
Assessed from date of first dose (Day 1) until date of intracranial progression at local site or death due to any cause or data cut off date whichever occurred first (up to 3 years 1 month), data for 6 months reported
Reported as:
Number · Percentage of participants
Intracranial Progression Free Survival in Participants With Brain Metastases at Baseline
Percentage of participantsTreatment Arm A: Osimertinib (AZD9291), Pemetrexed, Cisplatin or CarboplatinTreatment Arm B: Placebo for Osimertinib (AZD9291), Pemetrexed, Cisplatin or Carboplatin
Intracranial Progression Free Survival in Participants With Brain Metastases at Baseline81.8 (44.74 to 95.12)55.6 (20.42 to 80.45)
SecondaryIntracranial Progression Free Survival in Participants Without Brain Metastases at Baseline

Intracranial PFS (IC-PFS) is defined as time from randomization until intracranial progression per CNS RECIST 1.1 as assessed by the Investigator at local site or death due to any cause. For participants without brain metastases at baseline, the IC-PFS rate at specified timepoints was estimated using the Kaplan-Meier method which indicated the percentage of these participants who remain alive and free from intracranial progression per CNS RECIST 1.1 as assessed by the Investigator. The data was calculated throughout the study as per the below timeframe but IC-PFS rate at 6 months has been presented as it was clinically relevant.

Time frame:
Assessed from date of first dose (Day 1) until date of intracranial progression at local site or death due to any cause or data cut off date whichever occurred first (up to 3 years 1 month), data for 6 months reported
Reported as:
Number · Percentage of participants
Intracranial Progression Free Survival in Participants Without Brain Metastases at Baseline
Percentage of participantsTreatment Arm A: Osimertinib (AZD9291), Pemetrexed, Cisplatin or CarboplatinTreatment Arm B: Placebo for Osimertinib (AZD9291), Pemetrexed, Cisplatin or Carboplatin
Intracranial Progression Free Survival in Participants Without Brain Metastases at Baseline86.7 (68.08 to 94.83)63.1 (42.87 to 77.81)
Statistical analysis
  • Treatment Arm A: Osimertinib (AZD9291), Pemetrexed, Cisplatin or Carboplatin vs Treatment Arm B: Placebo for Osimertinib (AZD9291), Pemetrexed, Cisplatin or Carboplatin · Log Rank · Hazard ratio (hr): 0.56 · 95% CI 0.27 to 1.13A hazard ratio \< 1 favours Osi+Cis/Carbo+Pem to be associated with a longer progression-free survival than placebo.
SecondaryExtracranial Progression Free-survival

Extracranial PFS is defined as time from randomization until extracranial progression per RECIST 1.1 as assessed by the Investigator at local site or death due to any cause.

Time frame:
From date of first dose (Day 1) until date of extracranial progression at local site or death due to any cause or data cut-off date whichever occurred first (up to 3 years 1 month)
Reported as:
Median · Months
Extracranial Progression Free-survival
MonthsTreatment Arm A: Osimertinib (AZD9291), Pemetrexed, Cisplatin or CarboplatinTreatment Arm B: Placebo for Osimertinib (AZD9291), Pemetrexed, Cisplatin or Carboplatin
Extracranial Progression Free-survival8.4 (5.75 to 11.83)5.2 (3.52 to 5.78)
Statistical analysis
  • Treatment Arm A: Osimertinib (AZD9291), Pemetrexed, Cisplatin or Carboplatin vs Treatment Arm B: Placebo for Osimertinib (AZD9291), Pemetrexed, Cisplatin or Carboplatin · Log Rank · Hazard ratio (hr): 0.43 · 95% CI 0.26 to 0.71A hazard ratio \< 1 favours Osi+Cis/Carbo+Pem to be associated with a longer progression-free survival than placebo.
SecondaryOverall Survival (OS)

Overall survival is defined as the length of time from randomization until the date of death due to any cause.

Time frame:
From date of first dose (Day 1) until post progression survival follow-up (up to 3 years 1 month)
Reported as:
Median · Months
Overall Survival (OS)
MonthsTreatment Arm A: Osimertinib (AZD9291), Pemetrexed, Cisplatin or CarboplatinTreatment Arm B: Placebo for Osimertinib (AZD9291), Pemetrexed, Cisplatin or Carboplatin
Overall Survival (OS)15.9 (12.39 to 20.83)9.8 (8.38 to 17.25)
Statistical analysis
  • Treatment Arm A: Osimertinib (AZD9291), Pemetrexed, Cisplatin or Carboplatin vs Treatment Arm B: Placebo for Osimertinib (AZD9291), Pemetrexed, Cisplatin or Carboplatin · Log Rank · Hazard ratio (hr): 0.71 · 95% CI 0.42 to 1.23A hazard ratio \< 1 favours Osi+Cis/Carbo+Pem to be associated with a longer overall survival than placebo.

Adverse events

Collected over From date of first dose (Day 1) until Follow-up (28 days post last dose) (up to 3 years 1 month). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment Arm A: Osimertinib (AZD9291), Pemetrexed, Cisplatin or Carboplatin26/48 (54.2%)18/48 (37.5%)46/48 (95.8%)
Treatment Arm B: Placebo for Osimertinib (AZD9291), Pemetrexed, Cisplatin or Carboplatin28/48 (58.3%)15/48 (31.3%)47/48 (97.9%)
Most frequent serious events
Showing 10 of 40
Most frequent serious events
EventTreatment Arm A: Osimertinib (AZD9291), Pemetrexed, Cisplatin or CarboplatinTreatment Arm B: Placebo for Osimertinib (AZD9291), Pemetrexed, Cisplatin or Carboplatin
Platelet count decreasedInvestigations0/483/48
CellulitisInfections and infestations2/480/48
PancytopeniaBlood and lymphatic system disorders2/480/48
Pulmonary embolismRespiratory, thoracic and mediastinal disorders2/482/48
AppendicitisInfections and infestations1/480/48
Bronchopulmonary aspergillosisInfections and infestations1/480/48
COVID-19Infections and infestations0/481/48
COVID-19 pneumoniaInfections and infestations0/481/48
Device related infectionInfections and infestations1/480/48
PneumoniaInfections and infestations1/480/48
Most frequent other events
Showing 10 of 50
Most frequent other events
EventTreatment Arm A: Osimertinib (AZD9291), Pemetrexed, Cisplatin or CarboplatinTreatment Arm B: Placebo for Osimertinib (AZD9291), Pemetrexed, Cisplatin or Carboplatin
AnaemiaBlood and lymphatic system disorders30/4826/48
NauseaGastrointestinal disorders17/4823/48
AstheniaGeneral disorders19/4823/48
DiarrhoeaGastrointestinal disorders15/485/48
VomitingGastrointestinal disorders13/489/48
Neutrophil count decreasedInvestigations9/4812/48
ConstipationGastrointestinal disorders11/4811/48
NeutropeniaBlood and lymphatic system disorders10/489/48
Platelet count decreasedInvestigations10/482/48
Decreased appetiteMetabolism and nutrition disorders8/489/48

Baseline characteristics

The full analysis set consisted of all randomized participants.

Age, Continuous
Age, Continuous(Years)Treatment Arm A: Osimertinib (AZD9291), Pemetrexed, Cisplatin or CarboplatinTreatment Arm B: Placebo for Osimertinib (AZD9291), Pemetrexed, Cisplatin or CarboplatinTotal
Mean62.0 ± 11.3961.0 ± 10.0261.5 ± 10.68
Sex: Female, Male
Sex: Female, Male(Participants)Treatment Arm A: Osimertinib (AZD9291), Pemetrexed, Cisplatin or CarboplatinTreatment Arm B: Placebo for Osimertinib (AZD9291), Pemetrexed, Cisplatin or CarboplatinTotal
Female303969
Male191029
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment Arm A: Osimertinib (AZD9291), Pemetrexed, Cisplatin or CarboplatinTreatment Arm B: Placebo for Osimertinib (AZD9291), Pemetrexed, Cisplatin or CarboplatinTotal
Hispanic or Latino4711
Not Hispanic or Latino454287
Unknown or Not Reported000
08

Study locations

40 sites
  • Research Site
    Silver Spring, Maryland 20910, United States
  • Research Site
    Boston, Massachusetts 02114, United States
  • Research Site
    Beijing, 100005, China
  • Research Site
    Beijing, 100142, China
  • Research Site
    Ganzhou, 341099, China
  • Research Site
    Guangzhou, 510080, China
  • Research Site
    Jinan, 250013, China
  • Research Site
    Shenyang, 110001, China
  • Research Site
    Tianjin, 300060, China
  • Research Site
    Zhengzhou, 450008, China
  • Research Site
    Berlin, 12351, Germany
  • Research Site
    Cologne, 50937, Germany
  • Research Site
    Cologne, 51109, Germany
  • Research Site
    Hanover, 30625, Germany
  • Research Site
    München, D-80336, Germany
  • Research Site
    Beersheba, 84101, Israel
  • Research Site
    Jerusalem, 9103102, Israel
  • Research Site
    Jerusalem, 9112001, Israel
  • Research Site
    Kfar Saba, 4428164, Israel
  • Research Site
    Tel Aviv, 6423906, Israel
  • Research Site
    Tel Litwinsky, 52621, Israel
  • Research Site
    Florence, 50134, Italy
  • Research Site
    Meldola, 47014, Italy
  • Research Site
    Messina, 98158, Italy
  • Research Site
    Naples, 80131, Italy
  • Research Site
    Padova, 35128, Italy
  • Research Site
    Roma, 00168, Italy
  • Research Site
    Terni, 05100, Italy
  • Research Site
    Verona, 37124, Italy
  • Research Site
    Alicante, 03010, Spain
  • Research Site
    Barcelona, 08907, Spain
  • Research Site
    Córdoba, 14004, Spain
  • Research Site
    León, 24071, Spain
  • Research Site
    Madrid, 28040, Spain
  • Research Site
    Málaga, 29010, Spain
  • Research Site
    Murcia, 30008, Spain
  • Research Site
    Oviedo, 33011, Spain
  • Research Site
    Palma de Mallorca, 07010, Spain
  • Research Site
    Seville, 41013, Spain
  • Research Site
    Valencia, 46010, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Oct 2024, 37 months.

Results were first posted in Jan 2026, 1 year 2 months after primary completion.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 37 months is close to that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2021
First posted
Feb 21, 2021
StartActual
Sep 12, 2021
Primary completionActual
Oct 28, 2024
CompletionEst.
Jun 2, 2027
Results first posted
Jan 13, 2026
Last update
Jul 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04765059
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
Feb 21, 2021
Start date
Sep 12, 2021
Primary completion
Oct 28, 2024
Completion
Jun 2, 2027 (estimated)
Results posted
Jan 13, 2026
Last update
Jul 7, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Osimertinib

Start the discussion